# US 2016/0256571 A1 · Invention

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0256571 A1
- Document ID: US20160256571A1
- Status: Published application
- Kind: A1
- Application number: 14/389,368
- Filed: 2013-09-30
- Published: 2016-09-08
- Earliest claimed: 2013-09-30
- Applicants: Sanofi; Universite Pierre Et Marie Curie (Paris 6); Centre National De La Recherche Scientifique (C.N.R.S.); Institut National De La Sante Et De La Recherche Medicale (Inserm)
- Inventors: Marisol CORRAL-DEBRINSKI; Christopher LECHAUVE; Jose-Alain SAHEL; Thomas DEBEIR
- Web page: https://patentgrep.com/patent/US20160256571A1

## CPC

- A61K 48/0066: {Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid}
- A61K 38/1722: {Plasma globulins, lactoglobulins}
- A61K 38/42: Haemoglobins; Myoglobins
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 27/02: Ophthalmic agents
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2750/14171: Demonstrated in vivo effect
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention concerns a neuroglobin agonist for use in the treatment or prevention of a mitochondrial disease associated with respiratory chain complex I (RCCI) deficiency and/or respiratory chain complex III (RCCIII) deficiency.

## Claims

### Claim 1

A neuroglobin agonist for use in the treatment or prevention of a mitochondrial disease associated with respiratory chain complex I (RCCI) deficiency and/or respiratory chain complex III (RCCIII) deficiency.

### Claim 2 (depends on 1)

The neuroglobin agonist for the use of claim 1, wherein said mitochondrial disease is associated with Apoptosis Inducing Factor (AIF) deficiency.

### Claim 3 (depends on 1, 2)

The neuroglobin agonist for the use of claim 1 or 2, wherein said mitochondrial disease is not associated with a mutation or deletion of neuroglobin gene or is not induced by neuroglobin deficiency.

### Claim 4 (depends on 1, 2, 3)

The neuroglobin agonist for the use according to any one of claims 1 to 3, for restoring or improving RCCI and/or RCCIII function.

### Claim 5 (depends on 1, 2, 3, 4)

The neuroglobin agonist for the use according to any one of claims 1 to 4, wherein said mitochondrial disease associated with RCCI deficiency and/or RCCIII deficiency is a neurodegenerative disease or an ocular disease.

### Claim 6 (depends on 5)

The neuroglobin agonist for the use of claim 5, wherein said mitochondrial disease associated with RCCI deficiency and/or RCCIII deficiency is a retinal disease.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The neuroglobin agonist for the use according to any one of claims 1 to 6, wherein said neuroglobin agonist is a polypeptide selected from the group consisting of a dominant activated mutant of neuroglobin, a wild-type neuroglobin protein, a fragment and a peptidomimetic thereof.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6)

The neuroglobin agonist for the use of claim according to any one of claims 1 to 6, wherein said neuroglobin agonist is a nucleic acid which comprises an expression cassette comprising a polynucleotide encoding neuroglobin protein, said polynucleotide being operatively linked to at least one transcriptional regulatory sequence.

### Claim 9 (depends on 8)

The neuroglobin agonist for the use of claim 8, wherein said at least one transcriptional regulatory sequence comprises 3′UTR and/or 5′UTR neuroglobin sequence.

### Claim 10 (depends on 8, 9)

The neuroglobin agonist for the use of claim 8 or 9, wherein said at least one transcriptional regulatory sequence is one or more of a neuroglobin promoter, a retina specific promoter or a central nervous system specific promoter.

### Claim 11 (depends on 8, 9, 10)

The neuroglobin agonist according to any one of claims 8 to 10, wherein said expression cassette is inserted into an expression vector.

### Claim 12 (depends on 11)

The neuroglobin agonist for the use of claim 11, wherein said expression vector is a viral vector.

### Claim 13 (depends on 12)

The neuroglobin agonist for the use of claim 12, wherein said expression vector is an adeno-associated virus vector.

### Claim 14

A method for preventing or treating a mitochondrial disease associated with respiratory chain complex I (RCCI) deficiency and/or respiratory chain complex III (RCCIII) deficiency in a subject having or at risk of having such a disorder, comprising administration of a therapeutically effective amount of a neuroglobin agonist to the subject.

### Claim 15 (depends on 14)

The method of claim 14, wherein said mitochondrial disease is associated with Apoptosis Inducing Factor (AIF) deficiency.

### Claim 16 (depends on 14, 15)

The method of claim 14 or 15, wherein said mitochondrial disease is not associated with a mutation or deletion of neuroglobin gene or is not induced by neuroglobin deficiency.

### Claim 17 (depends on 14, 15, 16)

The method according to any one of claims 14 to 16, wherein said neuroglobin agonist is a nucleic acid which comprises an expression cassette comprising a polynucleotide encoding neuroglobin protein, said polynucleotide being operatively linked to at least one transcriptional regulatory sequence and wherein said method further comprises the step of expressing said polynucleotide in said subject.

### Claim 18 (depends on 14, 15, 16)

The method according to any one of claims 14 to 16, wherein said neuroglobin agonist is a polypeptide selected from the group consisting of a dominant activated mutant of neuroglobin, a wild-type neuroglobin protein, a fragment and a peptidomimetic thereof.
